CNS Drugs

Article	Citations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond	103
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review	99
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies	86
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment	81
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications	81
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination	74
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies	71
Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors	71
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status	69
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview	64
Intranasal Insulin for Alzheimer’s Disease	62
Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis	55
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis	49
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome	46
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression	43
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases	43
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys	43
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis	40
Siponimod: A Review in Secondary Progressive Multiple Sclerosis	39
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies	38
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis	37
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia	36
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies	35
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study	35
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia	34

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication	34
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders	34
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability	33
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain	33
Methadone for Pain Management: A Pharmacotherapeutic Review	32
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score	31
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia	30
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome	30
Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review	30
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status	29
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability	29
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)	28
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review	28
Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update	27
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches	27
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study	26
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis	26
Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System	25
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population	25
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis	25
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update	25
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy	25
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies	24
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis	24
Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures	23
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders	23
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)	23
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience	22
Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases	22
Efficacy, Tolerability, and Safety of Concentrated Intranasal Midazolam Spray as Emergency Medication in Epilepsy Patients During Video-EEG Monitoring	21
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment	20
Potential Role of Curcumin for the Treatment of Major Depressive Disorder	20
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment	20
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively	19
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder	19
Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke	19
Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease	19
Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials	18
Pharmacotherapy to Manage Central Post-Stroke Pain	18
COMT Inhibitors in the Management of Parkinson’s Disease	18
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs	18
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis	17
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Rece	17
Opicapone: A Review in Parkinson’s Disease	17
Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research	17
Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy	16
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations	16
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis	16
Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage	16
Risdiplam: A Review in Spinal Muscular Atrophy	16

A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD)	16
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval	16
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study	15
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data	15
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)	15
Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?	15
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis	14
Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review	14
Nusinersen: A Review in 5q Spinal Muscular Atrophy	14
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?	14
Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study	14
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study	14
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study	13
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder	13
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program	13
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy	13
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials	13
Treatment Options in Refractory Autoimmune Encephalitis	13
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis	13
Pharmacotherapy for Preschool Children with Attention Deficit Hyperactivity Disorder (ADHD): Current Status and Future Directions	12
Pharmacological Management of Apathy in Dementia	12
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants	12
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis	12
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies	12
Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN)	12
Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review	12
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use	12
Dextromethorphan/Bupropion: First Approval	12
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention	12
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives	12
Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease	12
Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)	11
New Oral Drugs for Migraine	11
Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study	11
Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands	11
β-Adrenoceptor Drugs and Parkinson’s Disease: A Nationwide Nested Case–Control Study	11
Efficacy and Safety of Ibuprofen Plus Paracetamol in a Fixed-Dose Combination for Acute Postoperative Pain in Adults: Meta-Analysis and a Trial Sequential Analysis	10
Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?	10
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study	10
Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis	10
Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?	10
Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features	10
Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials	10
The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies	10
Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Random	10
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders	10
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in H	10
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controll	10
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuatio	10
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden	9
Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy	9
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?	9
Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled T	9
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment	9
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments	9
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia	9
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions	9
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk	9
Pharmacotherapy for Frontotemporal Dementia	9
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study	9
Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents	9
Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review	9
Antiseizure Drugs and Movement Disorders	9
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts	8
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat	8
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder	8
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies	8
Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients	8
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial	8
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology	8
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders	8
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications	8
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Op	7
Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	7
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation	7
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing	7
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality	7
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia	7
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia	7
Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease	7

Risk of Major Adverse Cardiovascular Events Associated with Concomitant Use of Antidepressants and Non-steroidal Anti-inflammatory Drugs: A Retrospective Cohort Study	7
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex	7
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia	7
Potential of Glial Cell Modulators in the Management of Substance Use Disorders	7
Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain	7
OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use	7
Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials	7
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine	6
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research	6
Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients	6
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain	6
Current Principles in the Management of Drug-Resistant Epilepsy	6
Slowing Parkinson’s Disease Progression with Vaccination and Other Immunotherapies	6
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies	6
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies	6
The Efficacy and Safety of Concomitant Psychotropic Medication and Electroconvulsive Therapy (ECT)	6
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System	6
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy	6
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab	6
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study	6
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors	6
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression	6
Role of Pharmacogenomics in Individualizing Treatment for Alzheimer’s Disease	6
Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s Disease	6
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis	6
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis	6
The Options for Neuraxial Drug Administration	6
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials	6
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018	6
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophre	6
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder	6
The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder	6
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain	6